Atossa Therapeutics, Inc.
ATOS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001488039
No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Atossa Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 84 | 67 | −17 |
| Shares | 21.3M | 19.4M | −1.97M (−9.2%) |
| Value | $17.7M | $16.8M | −$918.4K (−5.2%) |
New holders (9)
Institutions that held Atossa Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Graham Capital Management, L.P. | 165,446 | $143.4K | 0.01% |
| Acadian Asset Management LLC | 97,287 | $82.0K | 0.00% |
| Gallagher Capital Advisors, LLC | 31,575 | $27.5K | 0.02% |
| Sigma Planning Corp | 24,000 | $20.8K | 0.00% |
| Rockefeller Capital Management L.P. | 5,000 | $4.33K | 0.00% |
| Huntington National Bank | 3,000 | $2.60K | 0.00% |
| NBC Securities, Inc. | 150 | $130 | 0.00% |
| SRS Capital Advisors, Inc. | 42 | $36 | 0.00% |
| Simplex Trading, LLC | 322 | $0 | 0.00% |
Sold out (26)
Institutions that held Atossa Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.